CJMB
CALLAN JMB INC.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
Last earnings +7.8% on 2026-03-31
$0.82
▲ +3.16%$0.82▼ -83.52%
over 1Y
L $0.70H $5.72
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.2%
1W+6.0%
1M+6.1%
3M-38.6%
YTD-27.1%
1Y-83.5%
Avoid
Conviction
Horizon
Long (>12mo)
Post-IPO cold-chain micro-cap burning cash faster than it holds, revenue halved since 2023 — unprofitable, dilutive, uninvestable.
Revenue $5.72M · FY2025
Callan JMB is a $4.6M micro-cap cold-chain logistics provider to life sciences whose top line is shrinking, not scaling: revenue fell from $13.2M (FY2023) to $6.56M (FY2024) to $5.72M (FY2025), a 57% two-year collapse. Management attributes the latest -13% to 'decrease in demand for our emergency preparedness services by certain states and local governments' — i.e., the business is concentrated in lumpy government contracts that are rolling off, not a growth engine. Gross profit is thin ($2.10M, 36.8% margin) and also declining. Whatever the 'disruptive' cold-chain pitch, the numbers show a business contracting.
The cost structure is the killer. SG&A exploded 77% to $8.6M against just $5.7M of revenue, driven by consulting/professional fees, IR and marketing for the IPO — plus a $542K impairment on property and equipment. That produced a -$7.03M operating loss (-122.9% operating margin) and a -$7.97M net loss (net margin -139.2%), with 'other expense' of -$935K adding insult. ROE is -342%, EPS -$1.82. Retained earnings swung to a -$10.3M accumulated deficit. Management explicitly warns it 'may continue to incur losses' and 'may never generate revenues sufficient to become profitable.'
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:08 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Is CJMB a buy? The one-page verdict, explained →
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $13.2M | $6.56M | $5.72M |
| Gross profit | $5.65M | $2.56M | $2.10M |
| Operating income | $2.20M | -$2.27M | -$7.03M |
| Net income | $2.18M | -$2.29M | -$7.97M |
| Diluted EPS | — | -$0.87 | -$1.82 |
| Net margin | 16.5% | -34.9% | -139.2% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.48M
EV / EBITDA—
EV / Sales0.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-172.9%
FCF yield-112.1%
Quality & risk
ROIC (est.)-238.7%
Free cash flow-$5.16M
Total debt$0.00
Net cash$2.13M
Altman Z-Score-4.37 distress
Piotroski F-Score1/8
Capital returns
Buyback yield—
Dividend yield (est.)72.2%
Shareholder yield72.2%
Shares Δ YoY+26.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Delisting notice2026-07-02
Item 3.01: further Nasdaq continued-listing deficiency notice — delisting risk escalating
- 8-K Officer / director change2026-06-11
Item 5.02: officer/director change amid mounting losses — leadership turnover
- 8-K Material agreement2026-05-27
Item 1.01: entered new material agreement (likely financing/customer)
- S-3 Shelf registration (potential raise)2026-05-26
Filed shelf registration to sell securities — future dilution overhang
- 10-Q Quarterly report2026-05-15
Q1'26 10-Q: cash-burning micro-cap, only $2.1M cash vs $4.6M annual burn
- 8-K Delisting notice2026-04-10
Item 3.01: received continued-listing deficiency notice from exchange
- 8-K Earnings results2026-03-31
FY25: revenue -13%, $7M operating loss, SG&A +77%, $542K impairment
- 10-K Annual report2026-03-31
FY25: revenue -13%, $7M operating loss, SG&A +77%, $542K impairment
- 8-K Material agreement2026-03-12
Item 1.01: entered material definitive agreement (financing/commercial)
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-292026-07-02open ↗8-KPeriod ending 2026-06-052026-06-11open ↗EFFECTFiling2026-06-05open ↗4Period ending 2026-05-272026-06-01open ↗8-KPeriod ending 2026-05-262026-05-27open ↗S-3Filing2026-05-26open ↗S-8Filing2026-05-26open ↗10-QPeriod ending 2026-03-312026-05-15open ↗SCHEDULE 13G/AFiling2026-05-13open ↗8-KPeriod ending 2026-04-072026-04-10open ↗10-KPeriod ending 2025-12-312026-03-31open ↗8-KPeriod ending 2026-03-312026-03-31open ↗
Frequently asked
- Is CALLAN JMB INC. (CJMB) a buy?
- CJMB currently carries a Avoid rating with 5/5 conviction, derived from its latest SEC filings. Post-IPO cold-chain micro-cap burning cash faster than it holds, revenue halved since 2023 — unprofitable, dilutive, uninvestable.
- What is CALLAN JMB INC.'s quality score?
- CJMB scores 42.795958023513165/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0002032545, latest 10-Q filed 2026-05-15) · EODHD · Proprietary analysis · as of 7/4/2026, 10:08:22 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.